NCT05132218View on ClinicalTrials.gov

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

UnknownOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2024

Conditions
ALK PositiveNSCLC Stage IIIBNSCLC Stage IV
Interventions
DRUG

Ensatinib

Prospective, exploratory, single-arm, multi-center, real-world research

Trial Locations (1)

100176

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

lead

Peking University Cancer Hospital & Institute

OTHER

NCT05132218 - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter